Overview

Safety Study of Tarceva in Children With Refractory and Relapsed Malignant Brain Tumors and Newly Diagnosed Brain Stem Glioma

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to establish the recommended dose/Maximum Tolerated Dose (MTD) of Tarceva in children as single agent and in combination with radiation therapy

Phase:

Phase 1

Details

Lead Sponsor:

Gustave Roussy, Cancer Campus, Grand Paris

Treatments:

Erlotinib Hydrochloride